Search Results
Apr 18, 2026, 19:44 ET BREAKTHROUGH PRIZE ANNOUNCES 2026 LAUREATES
patients with no family history of the diseases. It sheds light on the disease mechanisms, pointing in particular to multiple effects of toxic RNA and proteins in brain cells. It has established ALS and FTD – previously considered two largely separate disorders – on a disease spectrum, sharing
More news about: Breakthrough Prize
Apr 17, 2026, 11:00 ET CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
TherapiesPoster Board #: 18Abstract #: 144Title: Stepwise In Vivo CAR T Cell Engineering via Transient RNA Programming and RetroT All-RNA Genome IntegrationDate & Time: Monday, April 20, 2026, 9 AM–12 PM PTLocation: Poster Section 53Session
More news about: CREATE Medicines, Inc.
Apr 17, 2026, 03:48 ET Penetrium Bioscience Unveils Breakthrough Mechanism Solving 137-Year-Old "Seed & Soil" Paradigm, Opening a New Era for Targeted Cancer Therapy
Science and Technology). These studies confirmed that Penetrium's observed effects in pathological models are fully consistent with prior RNA sequencing (RNA-seq) data derived from pancreatic cancer organoids.This alignment provides strong evidence that Penetrium's mechanism is not limited to
More news about: Penetrium Bioscience
Apr 16, 2026, 09:53 ET Feromics Inc. Presents Functional Immunomics AI Platform at MIT AI Conference
diagnostics, and allogeneic donor selection.Once trained, these models can be applied to standard sequencing data—including bulk RNA-seq, single-cell RNA-seq, and retrospective clinical datasets—enabling scalable, real-world deployment.The platform supports three core application areas:
More news about: Feromics Inc.
Apr 16, 2026, 09:00 ET Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Apr 16, 2026, 08:00 ET Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant
More news about: Bio-Techne Corporation
Apr 15, 2026, 13:33 ET TEDCO's Maryland Innovation Initiative Announces More Than $2.1M to Latest Awardees
development; Johns Hopkins University; received $130,000Pratyush Tiwary: Emergente – Integrating AI and physics to model RNA structures with therapeutic potential; University of Maryland, College Park; received $130,000Stavroula Sofou: Affinity-cocktails
More news about: TEDCO
Apr 15, 2026, 12:05 ET Alida Biosciences Launches EpiPlex® Tri-Mod™ Service for Simultaneous Profiling of Three Key mRNA Modifications
NGS solution for simultaneous pseudouridine, m6A, and inosine detection in RNA.The new service expands the EpiPlex platform, which is designed to deliver sensitive and quantitative analysis of RNA modifications from RNA-limited clinical samples through an end-to-end workflow, including EpiScout™
More news about: Alida Biosciences
Apr 15, 2026, 09:04 ET Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
biologically active RNA-targeting small molecules. In addition to its neurodegeneration collaboration with Daiichi Sankyo, the company is advancing an internal pipeline including an oral small molecule inhibitor of c-Myc for solid tumors. Wayfinder Biosciences was founded by RNA scientists from the University
More news about: Wayfinder Biosciences, Inc.
Apr 15, 2026, 08:30 ET Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
patient whose tumor specimen is sent to Caris receives profiling through Whole Exome Sequencing (WES) of DNA, Whole Transcriptome Sequencing (WTS) of RNA and immunohistochemistry (IHC) analysis of proteins, covering more than 23,000 genes.A proprietary trial-matching platform then cross-references
More news about: Caris Life Sciences
Apr 15, 2026, 08:00 ET Wobble Genomics to Present Novel mRNA Sequencing Research at AACR 2026
therapeutic development during the conference.About Wobble GenomicsWobble Genomics is a biotechnology company developing advanced RNA sequencing technologies to unlock deeper biological insights and enable more precise, data-driven approaches to disease detection and treatment selection.Media
More news about: Wobble Genomics
Apr 15, 2026, 03:00 ET Cepheid and Oxford Nanopore Expand Partnership Following Successful Phase One Collaboration
generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing and the technology is in development for the analysis of other types of molecule including proteins. The technology is used in more than 125
More news about: Cepheid and Oxford Nanopore Technologies
Apr 14, 2026, 17:45 ET Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
data support the potential of BIZENGRI to address a critical unmet need for patients whose tumors are driven by NRG1 gene fusions. Tissue‑based RNA testing is essential to identify rare oncogenic fusions such as NRG1 and ensure patients with these actionable alterations are not overlooked,"
More news about: Partner Therapeutics, Inc.
Apr 14, 2026, 09:00 ET Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Apr 14, 2026, 05:50 ET Green Surfactants And Emulsifiers Market Set to Reach USD 2.73 Bn by 2035 as Sustainable Chemistry and Bio-Based Innovations Accelerate Global Industry Transformation: - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Apr 14, 2026, 03:00 ET ARTHEx Biotech Announces Participation at the 25th Annual Needham Virtual Healthcare Conference
Spain, April 14, 2026 /PRNewswire/ -- ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference,
More news about: ARTHEx Biotech
Apr 13, 2026, 11:33 ET Portable Blenders Market Set to Reach USD 764 Mn by 2035 Driven by Rising Health Awareness, and Innovation in Rechargeable Smart Kitchen Appliances - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Apr 10, 2026, 12:04 ET Stevia Sugar Blends Market to Reach USD 125 Billion by 2033 Amid Rising Health Awareness, Sugar Reduction Initiatives, and Expanding Demand for Natural Sweeteners - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Apr 10, 2026, 08:00 ET Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
player in the RNA therapeutics field, Vivatides has completed both its seed and Series A financings within less than one year of founding, underscoring strong investor confidence in the company's technological innovation and execution capabilities in extrahepatic RNA delivery. RNA therapeutics,
More news about: Vivatides Therapeutics
Apr 10, 2026, 07:00 ET Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
proliferation, metastasis and immune evasion. MUC16 is overexpressed in multiple tumor types with limited expression in normal tissue. A large-scale RNA analysis demonstrated that MUC16 is highly and stably expressed across ovarian cancers and in the most aggressive and most common subtypes of endometrial
More news about: Whitehawk Therapeutics, Inc.
Apr 09, 2026, 09:00 ET Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Apr 09, 2026, 07:30 ET Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
patients in H2 2026."Ronen Eavri, Co-founder & CEO of Barcode Nanotech, commented: "Barcode Nanotech has developed a library of novel lipids for RNA and DNA, LNP-based delivery, through a unique in vivo & AI-based screening platform which allow simultaneously screening of hundreds of different
More news about: Galmed Pharmaceuticals Ltd.
Apr 09, 2026, 03:53 ET Synthetic Biology Market Analysis 2026-2031: Genome Engineering Accounts for 33.21% Share, with Asia-Pacific as the Fastest-Growing Region, Says Mordor Intelligence
coverage."Synthetic Biology Market Segmentation OverviewBy Product Core ProductsDNA/RNA SynthesizersGene Editing Kits & EnzymesEnabling ProductsOligonucleotidesCloning VectorsEnabled
More news about: Mordor Intelligence Private Limited
Apr 08, 2026, 13:30 ET 3D Rendering Service Market to Reach USD 7.2 Billion by 2033 Driven by Expanding Adoption Across Architecture, Real Estate, Gaming, and Product Visualization Industries: Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Apr 07, 2026, 16:01 ET Insmed Provides Clinical Update on Phase 2b CEDAR Study
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe,
More news about: Insmed Incorporated